Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 10, 2022 | June 15, 2022 |
| Organon & Co.OGN · Entity 4115 | Chief Information Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date June 10, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,335 |
Reported balance
After 2022-06-10 transaction · row 1
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 15,556 · Balance 21,335 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2029-06-10 | Direct | 13,882 |
Reported balance
After 2022-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-10 · Grant · Acquired 13,882 · Balance 13,882 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.54 · Expires 2027-05-28 | Direct | 3,448 |
Reported balance
Holding disclosure · report date 2022-06-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,448 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.90 · Expires 2028-06-02 | Direct | 3,714 |
Reported balance
Holding disclosure · report date 2022-06-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,714 |
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,105.292 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 6,555 · Balance 110,256.292 Row 2 · 2026-03-31 · Tax withholding · Disposed 2,246 · Balance 108,010.292 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 12,312 · Balance 120,322.292 Row 4 · 2026-03-31 · Tax withholding · Disposed 4,217 · Balance 116,105.292 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 183,639 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 183,639 · Balance 183,639 F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 6,555 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,625 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,312 · Balance 24,625 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 7 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 12,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 6 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 183,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,639 Underlying: Common Stock · 183,639 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,217 | $5.70 | $24,036.90 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,105.292 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,322.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,246 | $5.70 | $12,802.20 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,010.292 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,256.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,201 Underlying: Common Stock · 8,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,809 | $5.84 | $16,404.56 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,701.292 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,510.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,240 | $7.23 | $16,195.20 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,310.292 F3 · balance_after: Includes the addition of 2,076.678 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 6,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,473.614 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 8,475 | $7.17 | $60,765.75 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,933.614 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 23,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,408.614 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 11 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 10 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,555 Underlying: Common Stock · 6,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 9 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,401 Underlying: Common Stock · 8,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 36,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 8 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,937 Underlying: Common Stock · 36,937 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 181,518 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 7 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,518 Underlying: Common Stock · 181,518 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,763 | $14.51 | $25,581.13 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 6 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,230.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,993.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,645 | $14.51 | $38,378.95 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,414.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,059.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,809 | $14.51 | $40,758.59 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,504.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,313.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 17:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 881 | $15.29 | $13,470.49 |
DisclosureSEC source: 0001679854-25-000002 · wk-form4_1740434806.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,113.614 F3 · balance_after: Includes the addition of 5,342.614 shares of Common Stock acquired from dividend reinvestments not previously reported. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 17:06 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001679854-25-000002 · wk-form4_1740434806.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,652 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 17:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 5,142 | $14.92 | $76,718.64 |
DisclosureSEC source: 0001679854-25-000002 · wk-form4_1740434806.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,081 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 17:06 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 14,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001679854-25-000002 · wk-form4_1740434806.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,223 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,645 | $20.35 | $33,475.75 |
DisclosureSEC source: 0001821825-24-000101 · wk-form4_1725568302.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,186 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000101 · wk-form4_1725568302.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,831 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:04 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000057 · wk-form4_1715112267.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:04 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,045 | $19.61 | $20,492.45 |
DisclosureSEC source: 0001821825-24-000057 · wk-form4_1715112267.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,237 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:04 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000057 · wk-form4_1715112267.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · derivative · entry 6 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,110 Underlying: Common Stock · 6,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · derivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,579 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,245 | $18.80 | $42,206.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,233 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 6,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,478 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,226 | $18.80 | $23,048.80 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,924 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,150 Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 100,762 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000020 · wk-form4_1712089246.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,762 Underlying: Common Stock · 100,762 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 24,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000020 · wk-form4_1712089246.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,601 Underlying: Common Stock · 24,601 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,117 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,326 | $18.04 | $78,041.04 |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,572 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,895 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,418 | $21.53 | $95,119.54 |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,781 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028104 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,049 Underlying: Common Stock · 3,046 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:45 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,044 | $24.24 | $25,306.56 |
DisclosureSEC source: 0001209191-23-028104 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,304 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.